General Practice in Bellflower, CA
5 verified general practice doctors in Bellflower.
General practice physicians provide broad, first-contact medical care for common conditions across all age groups.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. Edgardo Binoya, MD
General Practice
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. John Vander Hulst, MD
General Practice
CMS Open Payments· $26.99 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$26.99
Total received
1
Transactions
1
Paying companies
Top paying companies
Among the 13,209 general practice doctors we've analyzed, about 25% received any industry payment (median $145 among those who did). This doctor's total ranks around the 79th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US general practice doctors.
Payments to John Vander Hulst do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Michael Seroka, MD
General Practice
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Rajendra Sheth, MD
General Practice
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Nha Doan, MD
General Practice
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.